Roboligent, a company that leads the robot service automation market based on its hyper-precise force control technology, announced today that it has been selected as a resident company of Johnson & Johnson Innovation – JLABS @ TMC.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. Roboligent is seeking to accelerate the innovation of its first commercialized product, the Regen rehabilitation therapy automation robot.
Regen is a rehabilitation therapy automation robot that helps patients with upper and lower limb rehabilitation needed due to stroke or other diseases by learning the patient’s movement patterns and strength, adapting to the patient’s condition, and safely performing repetitive exercise therapy. In addition, Regen can quantitatively evaluate the patient’s exercise ability, unlike the previous method in which a skilled therapist evaluated it in a qualitative way, and can increase the motivation for recovery by enabling tracking and observation of the patient’s exercise content and recovery process. Therefore, it has the advantage of being able to set a more systematic exercise therapy plan.